Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sensorion
  6. News
  7. Summary
    ALSEN   FR0012596468

SENSORION

(ALSEN)
  Report
Real-time Euronext Paris  -  11:35:21 2023-01-26 am EST
0.3750 EUR   -0.66%
01/03Sensorion Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity
AQ
01/03Sensorion : Inside Information / Other news releases
PU
01/03Sensorion Recruits First Patient In Mid-stage Study Of Hearing Loss Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sensorion's Gene Therapy for Hearing Loss Wins Rare Pediatric Disease Tag in US

11/07/2022 | 02:57am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about SENSORION
01/03Sensorion Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial ..
AQ
01/03Sensorion : Inside Information / Other news releases
PU
01/03Sensorion Recruits First Patient In Mid-stage Study Of Hearing Loss Drug
MT
01/03Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Tri..
CI
2022Sensorion Wins US FDA's Orphan Drug Tag for Hearing Loss Gene Therapy
MT
2022Sensorion's Gene Therapy for Hearing Loss Wins Rare Pediatric Disease Tag in US
MT
2022Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the..
CI
2022Sensorion Wins Regulatory Nod to Launch Mid-Stage Study of Cisplatin-Induced Hearing Lo..
MT
2022Sensorion SA Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical ..
CI
2022Sensorion SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
More news
Financials
Sales 2022 5,53 M 6,00 M 6,00 M
Net income 2022 -21,4 M -23,2 M -23,2 M
Net Debt 2022 20,1 M 21,8 M 21,8 M
P/E ratio 2022 -1,39x
Yield 2022 -
Capitalization 30,0 M 32,5 M 32,5 M
EV / Sales 2022 9,04x
EV / Sales 2023 12,2x
Nbr of Employees 38
Free-Float 50,7%
Chart SENSORION
Duration : Period :
Sensorion Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SENSORION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,38 €
Average target price 2,80 €
Spread / Average Target 647%
EPS Revisions
Managers and Directors
Nawal Ouzren Chief Executive Officer & Director
Scott D. Myers Chairman
Géraldine Honnet Chief Medical Officer
Eric Forquenot de la Fortelle Independent Director
Julien Miara Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SENSORION2.03%33
MODERNA, INC.9.54%74 174
LONZA GROUP AG15.21%42 087
IQVIA HOLDINGS INC.10.55%42 070
ALNYLAM PHARMACEUTICALS, INC.-4.01%28 176
SEAGEN INC.7.39%25 624